Objective: To identify predictors of receiving psychoactive medication and receiving recommended first-line pharmacotherapy in individuals with newly diagnosed late-life depression.
Key Words: Canada, depression, elderly, pharmacotherapy, population-based L ate-life depression is a major public health problem. Major depression occurs in 1% to 20% of the general elderly population (1) (2) (3) (4) , while clinically significant depression occurs in up to 20% of seniors living in the community (2) and 37% of those treated in primary care (5) . Depressive disorders in the elderly are associated with increased risks for impaired physical and emotional health (2) , pain (6) , loss of productivity (2) , mortality from medical conditions (7) and suicide (2) , and increased use of medical and mental health services (2, (8) (9) (10) . Late-life depression is associated with poor prognosis: one metaanalysis of elderly individuals suffering from depression in the community and in primary care reported that, at 24-month follow-up, only 33% were well, 33% suffered from depression, and 21% had died (5) .
Given the pervasiveness and impact of late-life depression, delivery of effective treatment is essential to improving quality and length of life. Most seniors with depression are treated in primary care (11) . Many receive inadequate treatment (3, (12) (13) (14) (15) (16) (17) , although clinical practice guidelines have been developed to assist practitioners with treatment. In 2001, the CPA released its Clinical Guidelines for the Treatment of Depressive Disorders (18) that included recommendations tailored to individuals aged 65 years and older. Effective treatments included pharmacotherapy, electroconvulsive therapy for patients with significant medical comorbidity and less tolerability to pharmacotherapy, and psychotherapy for mild-to-moderate depression (18, p 63S-76S). The Guidelines also specified first-, second-and third-line pharmacotherapies, all of which are antidepressants.
As the Canadian population ages, the issue of receiving appropriate treatment for late-life depression assumes greater importance. We undertook this research to compare the pharmacotherapies dispensed in response to a new depression diagnosis with existing guidelines. Our study aimed to determine the factors predicting receipt of psychoactive medication and first-line pharmacotherapy in Quebec seniors with new episodes of depression. Identifying the determinants of appropriate treatment is the first step to reducing disability, poor quality of life, increased risk for death, and avoidable use of medical and mental health care services.
Methods

Study Design and Data Source
We conducted a population-based, retrospective cohort study based on data we obtained from the databases of the RAMQ (the Quebec health insurance board), which remunerates physicians for services and administers the Quebec public drug insurance plan. In 2002, the public drug insurance plan covered approximately 871 800 residents aged 65 to 85 years (19) . Using unique encrypted numbers for patients and physicians to maintain anonymity, we linked 3 RAMQ databases at the patient level. We obtained data on patient age, sex, and region of residence from the beneficiaries database. Diagnoses and diagnosing physician specialty were obtained from the medical services database. Drug name, type of medication, quantity and concentration, date prescription filled, and prescribing physician specialty were obtained from the pharmaceutical database. The latter database is based on prescription claims for drugs dispensed and has been shown to be reliable and valid (20) .
Identification of Study Subjects
We identified beneficiaries aged 65 to 84 years and having a new diagnosis of depressive disorder given by either a primary care physician (for example a family medicine physician, internist, or geriatrician) or a psychiatrist between October 1, 2000, and March 31, 2001 (a 6-month case identification period). We obtained all pharmaceutical records from October 1, 1999, to March 31, 2002 . There were 2 observation periods: first, a follow-up 1-year period from the date of the first diagnostic coding of depression, during which subjects had to remain alive; and second, an antecedent 1-year period from the date of the first diagnostic coding of depression, during which subjects having a depression diagnosis were excluded, to retain patients with new-onset disorders.
Diagnostic Codes for Depression
We used the first diagnostic coding of depressive disorder during the case identification period to identify patients with depression. One diagnosis per physician visit was provided, irrespective of whether medication was prescribed. Although the RAMQ uses diagnostic codes from the ICD-9 (21), some physicians may have substituted DSM-IV (22) diagnostic codes that are more detailed for mental health disorders. To compensate for this discrepancy, we created an algorithm to retain patients with probable depression. Our physician experts identified 19 diagnostic codes that might have been used to indicate depression (Table 1) ; of these, we selected the codes for which diagnoses were common to both the ICD-9 
Study Medications
Psychoactive medications were identified from a comprehensive medication list used by the RAMQ. We assigned 9 medication classes: antidepressants, anticonvulsants, anxiolytics, barbiturates, benzodiazepines, lithium, major tranquilizers, stimulants, and others (for example, levodopa and sumatriptan). Medication use was defined as having at least one prescription claim for a study medication. New users of antidepressants were those who had no antidepressant pharmacy claim in the 365 days preceding diagnosis. Low-dose trazodone (for example daily dosage under 150 mg) was not classified as an antidepressant because it is used to aid sleep. We created a comorbidity score based on pharmacy claims data (23) .
Outcomes
We defined receipt of psychoactive medication as having at least one dispensing claim for a study drug in the year following diagnosis, beginning with the day of diagnosis. We defined receipt of recommended first-line pharmacotherapy as having a dispensing claim for a first-line medication at the first prescribing visit, defined as the visit during which psychoactive medication was initially prescribed (which could have occurred concurrently with, or following, diagnosis). First-line pharmacotherapies listed by the CPA Guidelines (18) included the antidepressants moclobemide, citalopram, bupropion, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, and venlafaxine. In contrast to other late-life depression guidelines (24), fluoxetine was not considered first-line because it has a long half-life that increases the risk for drug interactions (18, 25) .
Prior to beginning this study, we obtained approval from the University of Montreal, Faculty of Medicine Research Ethics Committee.
Statistical Analysis
Descriptive statistics were used to characterize the study sample. To compare subjects by sex, we used t tests and chi-square tests as appropriate. Psychoactive medication dispensed was compared by diagnosis with chi-square and Fisher's exact tests. To account for possible dependence among different patients of the same physician, we employed a generalized estimating equations approach (26) for the 2 binary outcomes. This statistical method accounts for clustered data and for the unbalanced structure of the data, in that the number of patients 27, 28) , which indicated that there were 2433 distinct physician clusters with patient numbers ranging from 1 to 14. Predictors of receiving psychoactive medication were evaluated among all patients in the study (n = 5258). Predictors of receiving recommended first-line pharmacotherapy were evaluated only among patients dispensed psychoactive medication (because it is possible that either psychotherapy or electroconvulsive therapy was the treatment of choice) and who had not received antidepressants in the year prior to diagnosis (n = 2623) (because it is possible that the originally dispensed antidepressant was switched if patients experienced side effects or failed to respond). For receipt of psychoactive medication, the candidate variables included patient age, sex, region of residence (urban or rural), diagnosis (dysthymia or depression NOS), and diagnosing physician specialty (primary care physician or psychiatrist). For receipt of recommended first-line pharmacotherapy, the candidate variables included these as well as having the same physician diagnosing and treating the patient (yes or no), and receiving the medication within 31 days of diagnosis (yes or no). Two-tailed P values less than 0.05 were considered statistically significant.
Results
Patient Characteristics
We identified 5258 seniors with a new diagnosis of depressive disorder during the case-identification period (Table 2) . Patient characteristics are presented in Table 2 according to sex. Most patients were dispensed psychoactive medication in the year following diagnosis (84.1%) and did not receive antidepressants in the preceding 365 days (64.3%). Of those given psychoactive medication, 3244 (73.4%) were diagnosed and treated by the same physician; 3840 (86.9%) received medication in the month following diagnosis; and 2623 (59.3%) had not received antidepressants in the previous year. More patients who were diagnosed and treated by the same physician received medication within the month of diagnosis, compared with those having different diagnosing and prescribing physicians (78.1% and 42.0%, respectively; P = 0.0001).
Pharmacotherapy Preceding and Following Depression Diagnosis
Psychoactive medication use increased following diagnosis.
In the year prior to diagnosis, patients were prescribed antidepressants (35.7%), benzodiazepines (58.2%), major tranquilizers (7.4%), anxiolytics (4.5%), anticonvulsants (2.9%), lithium (1.4%), stimulants (0.3%), and barbiturates (0.5%). In the year following diagnosis, patients were prescribed antidepressants (64.2%), benzodiazepines (61.7%), major tranquilizers (12.1%), anxiolytics (5.0%), anticonvulsants (4.6%), lithium (1.6%), stimulants (0.5%), and barbiturates (0.6%). Women, compared with men, received more antidepressants (39.1% and 28.1%, respectively; P = 0.0001), benzodiazepines (61.9% and 49.7%, respectively; P = 0.0001), and anxiolytics (5.0% and 3.4%, respectively; P = 0.0114) prior to diagnosis. Women also received more antidepressants; (63.3% and 55.6%, respectively; P = 0.0001) (66.5% and 58.8%, respectively; P = 0.0001) and benzodiazepines (64.4% and 55.6%, respectively) P = 0.0001) following diagnosis.
Psychoactive Medication Dispensed at the First Prescribing Visit
Antidepressants (63.6%) and benzodiazepines (45.3%) were the most commonly dispensed medications at the first prescribing visit. Patients with depression NOS received more antidepressants than did patients with dysthymia (59.9% and 42.8%, respectively; P = 0.0001). Patients with dysthymia received more benzodiazepines (50.3% and 43.7%, respectively; P = 0.0001), major tranquilizers (13.0% and 6.2%, respectively; P = 0.0001), and stimulants (0.6% and 0.2%, respectively; P = 0.0223). Psychoactive medication was dispensed to more patients diagnosed by their primary care physicians than by their psychiatrists (85.4% and 77.3%, respectively; P = 0.0001). Fewer psychiatrists' patients, compared with primary care physicians' patients, received antidepressants (37.7% and 58.9%, respectively; P = 0.0001). However, more psychiatrists' patients received stimulants (0.8% and 0.1%, respectively; P = 0.0003) and major tranquilizers (20.1% and 4.0%, respectively; P = 0.0001). In univariate analyses, female sex, depression NOS, comorbidity, and diagnosing primary care physicians were associated with increased odds of receiving psychoactive medication (Table 3 , left side). In multivariate analysis, female sex, depression NOS, increasing comorbidity, and Table 3 , right side) indicated that male sex , depression NOS, living in rural areas, having a diagnosing primary care physician, having the same diagnosing and prescribing physician, and receiving the medication within 31 days of diagnosis were associated with increased odds of receiving first-line pharmacotherapy. In multivariate analysis, male sex, depression NOS, having the same diagnosing and prescribing physician, and receiving the medication within 31 days of diagnosis were independently associated with increased odds of receiving recommended first-line pharmacotherapy.
Discussion
We examined the psychoactive medication claims data in Quebec for seniors with newly diagnosed depression during 2000-2002. Eighty-four percent of patients were dispensed psychoactive medication following diagnosis; of these patients, 87% received this medication shortly after diagnosis. Women were more likely than men to receive psychoactive medication, a finding which corroborates that of others (30) , and may be due to either increased disease severity or greater health care-seeking behaviour by women with depression (30, 31) . Depression NOS increased the likelihood of receiving psychoactive medication, possibly because physicians used this diagnostic code to indicate major depression in the absence of such a code in the ICD-9 (21). By contrast, ICD-9 codes exist for both dysthymia and bipolar disorder (21) . Possibly, patients with medical comorbidity were more likely to receive psychoactive medication because they had poorer quality of life and functioning, compared with patients without comorbid conditions (32) . Patients residing in urban areas were less likely to receive psychoactive medication, possibly because they had easier access to psychotherapy. A sensitivity analysis performed on a subsample that excluded previous users of antidepressants supported these findings.
Most late-life depression was diagnosed and treated in general practice. Greater proportions of women than men were older, diagnosed with depression NOS, diagnosed by primary care physicians, received more medication after diagnosis and within 31 days, had the same diagnosing and treating physician, and received antidepressants prior to diagnosis. Use of most psychoactive medications increased following diagnosis-especially use of antidepressants, which rose from 36% in the year prior to diagnosis to 64% in the subsequent year. By comparison, benzodiazepine use was high prior to and subsequent to diagnosis, which mirrors others' findings (33, 34) and suggests that use is long-term. Although one Canadian study found that elderly subjects with depression were more likely to be prescribed benzodiazepines than antidepressants (35) , only 18% of patients in our study received benzodiazepines without antidepressants. The finding that benzodiazepine prescribing persists, despite evidence of increased risks for recurrence and relapse of depression (36), as well as for cognitive problems (35, 37) and falls in elderly patients (38) , should raise concerns about appropriate prescribing for the elderly. Psychiatrists possibly prescribed psychoactive medication less often than primary care physicians because they provided psychotherapy.
Having the same physician diagnosing and treating the depression was the strongest predictor of receiving recommended first-line pharmacotherapy. Relational continuity (39) was more common among primary care physicians than psychiatrists (81.9% and 25.3%, respectively; P = 0.0001) and among patients dispensed psychoactive medication soon after diagnosis (78.1% and 42.0%, respectively; P = 0.0001), suggesting that long-standing relationships with primary care physicians are important to receiving appropriate pharmacotherapy. Because the Guidelines (18) were developed for the treatment of depression, we regenerated the analyses for first-line pharmacotherapy and excluded patients with dysthymia. The results corroborated our initial findings, although lower comorbidity became a significant predictor (OR 0.97; 95%CI, 0.60 to 0.92; P = 0.0275). Collectively, these findings support the notion that older patients are more likely to follow suggestions from physicians they know well. Despite having documented depressive disorders, women were less likely than men to receive first-line pharmacotherapy, even though they were more likely to receive psychoactive medication. Sex differences in care received are reported in other health areas as well (40) (41) (42) , pointing to the need for further research to elucidate why guidelines and accepted standards of practice are followed less often in women's, compared with men's, health care.
Population administrative databases provide many advantages but are not without their shortcomings. Validity of diagnoses cannot be established, although physicians tend to underdiagnose depression (10, (43) (44) (45) . Pharmacy claims were proxies for patient consumption and (or) physician prescribing. However, comparison of claims records to patient self-report of antidepressant use is satisfactory (kappas0 .70) (46, 47) . Information on case severity, medication samples provided (46) , and use of psychotherapy by psychologists and other allied health professionals was missing from the RAMQ databases. The generalizability of our findings may be limited to elderly patients with uncomplicated depression because we excluded patients diagnosed with other psychiatric conditions in the previous year. Notwithstanding these limitations, this study is population-based and includes seniors from all socioeconomic strata. We studied only patients with diagnosed depression because antidepressants may be prescribed for medical conditions not addressed by depression practice guidelines. Finally, by focusing on new episodes of depression and the initial medication dispensed, we evaluated receipt of first-line pharmacotherapy recommended at the time of the study.
In conclusion, most seniors with newly diagnosed depression received psychoactive medication, although many did not receive recommended first-line pharmacotherapy. The finding that male sex was associated with receiving recommended first-line pharmacotherapy may increase physicians' awareness that women are at risk for not receiving appropriate medication. The finding that benzodiazepines were dispensed to nearly one-half of treated patients may raise concerns about prescribing patterns because these medications may worsen depression or lead to adverse events. Of pivotal importance, relational continuity was the strongest predictor of receiving recommended first-line pharmacotherapy, suggesting that the patient-provider relationship is key to receiving appropriate medication. Résultats : Un total de 4 421 (84,1 %) patients ont reçu une médication psychotrope suivant le diagnostic; 2 623 (59,3 %) patients n'avaient pas reçu d'antidépresseurs dans l'année précédente. Parmi ceux-ci, 1 310 (49,9 %) patients ont reçu la pharmacothérapie de première ligne recommandée. Les prédicteurs indépendants de la réception d'une médication psychotrope étaient le sexe féminin, la dépression non spécifiées (NS), la comorbidité croissante, et le fait de vivre en milieu rural. Les prédicteurs indépendants de la réception de la pharmacothérapie de première ligne recommandée étaient le sexe masculin, la dépression NS, la réception d'un médicament dans le mois suivant le diagnostic, et le même médecin diagnostiquant et traitant le patient.
Conclusion :
Le sexe masculin et la continuité des soins prédisaient que les patients recevaient la médication recommandée.
